A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung cancer

A prospective observational study of immune-checkpoint inhibitor (Nivolumab) treatment in patients with non-small cell lung cancer - A prospective observational study of Nivolumab treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000021600

Enrollment

Registered

2016-03-24

Start date

2016-03-03

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Diagnosed with non-small cell lung cancer 2)Scheduled for administration of Nivolumab 3)With written informed consent

Exclusion criteria

Exclusion criteria: None

Design outcomes

Primary

Measure	Time frame
Monitoring a progress of Nivolumab treatment for non-small cell lung cancer patients	—

Countries

Japan

Contacts

Public ContactTomoya Fukui

Kitasato University School of Medicine Department of Respiratory Medicine

tofukui@med.kitasato-u.ac.jp042-778-8111

Outcome results